Corona Remedies Limited (NSE: CORONA) and Eris Lifesciences Ltd (NSE: ERIS) are both listed in the Pharmaceuticals industry. Corona Remedies has a market capitalisation of ₹13,278 Cr and Eris Lifesciences ₹16,096 Cr, as of 9 Nov 2026. Their P/E ratios are 71.7 and 25.6 respectively. Return on equity is 24.79% for Corona Remedies and 18.07% for Eris Lifesciences.
| Metric | Corona Remedies | Eris Lifesciences |
|---|---|---|
| NSE Symbol | CORONA | ERIS |
| BSE Code | 544644 | 540596 |
| Share Price | ₹2,545.70 | ₹1,255.50 |
| Market Cap | ₹13,278 Cr | ₹16,096 Cr |
| P/E Ratio | 71.7 | 25.6 |
| Return on Equity | 24.79% | 18.07% |
| Return on Assets | 14.99% | 7.30% |
| Dividend Yield | 0.46% | 1.24% |
| Beta (1Y) | 0.24 | 0.07 |
| 1-Year Price Change | — | -21.1% |
| 3-Month Price Change | +22.3% | -9.9% |
| 52-Week Range | ₹1,336.60 – ₹2,719.30 | ₹1,069.00 – ₹1,740.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹441 Cr | ₹892 Cr |
| Quarterly Net Profit | ₹60 Cr | ₹187 Cr |
| Net Margin | 13.7% | 21.0% |
| EPS (Basic, Quarter) | ₹9.86 | ₹13.26 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor…
Eris Lifesciences has a market capitalisation of ₹16,096 Cr, against ₹13,278 Cr for Corona Remedies as of 9 Nov 2026, about 1.2 times the size by market cap.
Corona Remedies has a P/E of 71.7 and Eris Lifesciences a P/E of 25.6 as of 9 Nov 2026.
Corona Remedies has a return on equity of 24.79% and Eris Lifesciences 18.07%.
Corona Remedies reported revenue of ₹441 Cr and net profit of ₹60 Cr for Q2 FY27. Eris Lifesciences reported revenue of ₹892 Cr and net profit of ₹187 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.